Please log in to view this page
Username
Password
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
